A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

NCT04380805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Cervical Cancer
Metastatic Cervical Cancer

Interventions

BIOLOGICAL: AK104

Sponsor

Akeso

Collaborators

[object Object]